scholarly journals Parameters of endothelial function and insulin resistance in patients with metabolic syndrome before and after weight loss

2008 ◽  
Vol 5 (1) ◽  
pp. 18-22 ◽  
Author(s):  
A M Mkrtumyan ◽  
E V Biryukova ◽  
N V Markina ◽  
M A Garbuzova

In clinical practice, physicians of different specialties often faced with the metabolic syndrome (MS) is a set of hormonal and metabolic disorders that share a common pathophysiological mechanism - insulin resistance (IR) [1, 5, 11]. MS is important for the clinician not only how widespread pathology, but primarily as a life-threatening condition. Of course, this syndrome plays an important role in accelerating the development and progression of diseases associated with atherosclerosis, which, according to experts WHO, ranks first among the causes of mortality in industrialized countries [12, 16, 19]. This situation is particularly important for Russia due to the relatively high spread of the syndrome, component, according to several authors, about 20% of the population, and high rates of death from coronary heart disease and stroke in the Russian population [2, 4, 5]. It is known that the risk of coronary heart disease (CHD), stroke, and total coronary mortality increases with the number of components of metabolic syndrome [14, 15, 20]. The study J.H. Park et al., Which included 478 patients with ischemic stroke, MS was diagnosed in 53.4% of patients (criteria NCEP ATP III), the thickness of the complex value of the index "intima-media" of the carotid arteries was increased in direct proportion to an increase in the number of available components of MS [20] . Link between R D and cardiovascular disease, apparently, is endothelial dysfunction, which is the study at various metabolic diseases received much attention [9, 10, 22]. Endothelial dysfunction, which is typical for many patients with MS, is a marker of metabolic and vascular disorders [15, 22]. In the initial period of development of the atherosclerotic process, even when there are no obvious clinical manifestations and visible morphological changes of blood vessels, the main role is played by endothelial dysfunction [9, 21]. Endothelial dysfunction is also discussed as one of the reasons for the rapid development, progression of atherosclerosis and its complications in patients with MS [11,18]. For example, recent studies have shown that tears plaques leading to myocardial infarction, do not always occur in the zone of maximum stenosis of the coronary arteries [13]. Rather, they tend to occur in places restrictions of small - less than 50% by angiography. The study of endothelial function in patients with MS is at the initial stages of the study [8, 15, 18]. In addition, of particular interest is the study of the effect of weight loss on the state of the endothelium in the syndrome of insulin resistance.

2013 ◽  
Vol 94 (2) ◽  
pp. 152-157
Author(s):  
O V Arsenitcheva ◽  
M G Omeljanenko

Aim. To assess the influence of endothelial dysfunction and metabolic syndrome on interventional treatment coronary complications development in patients with coronary heart disease. Methods. 57 patients with coronary heart disease and concomitant metabolic syndrome (the main group) and 64 patients with coronary heart disease alone (the comparison group) were included in the study. Control group for endothelial function parameters included 33 healthy blood donors. Endothelial function was assessed by plasma and erythrocyte nitrate level, plasma L-arginine level and desquamated endothelial cell blood count before the interventional treatment and after its completion. Results. Initial signs of endothelial dysfunction were observed in both groups of patients compared to the controls. Desquamated endothelial cell blood count was significantly higher in patients with metabolic syndrome than in the comparison group. Only the desquamated endothelial cell blood count increased significantly after the interventional treatment, the difference was more pronounced (р 0.05) in patients with metabolic syndrome. Complications of interventional treatment in patients with and without symptoms of metabolic syndrome were observed in 29.8 and 14.1% respectively (р 0.05). The number of coronary artery restenoses was significantly higher in the main group than in the comparison group (12.2 and 3.1% respectively). Conclusion. Initially endothelial dysfunction was more pronounced in patients with metabolic syndrome. A significant increase of endothelial dysfunction was observed in patients of the main group after the interventional treatment. The number of interventional treatment complications and coronary arteries restenoses was significantly higher in patients with coronary heart disease and concomitant metabolic syndrome.


2011 ◽  
Vol 7 (3) ◽  
pp. 219-227 ◽  
Author(s):  
Francesco Angelico ◽  
Lorenzo Loffredo ◽  
Pasquale Pignatelli ◽  
Teresa Augelletti ◽  
Roberto Carnevale ◽  
...  

2007 ◽  
Vol 10 (4) ◽  
pp. 204-209 ◽  
Author(s):  
Sameer Nagamia ◽  
Anbu Pandian ◽  
Faiz Cheema ◽  
Rama Natarajan ◽  
Qamar A. Khan ◽  
...  

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Julie K Bower ◽  
Vijay Nambi ◽  
Mariana Lazo ◽  
Andreea Rawlings ◽  
Meredith C Foster ◽  
...  

Introduction. Fasting glucose (FG) is part of the Adult Treatment Panel III (ATP III) criteria for defining the metabolic syndrome (MetS). Glycated hemoglobin (HbA1c) is a measure of 2-3 month endogenous glucose exposure and is now recommended for diabetes diagnosis and screening for high-risk individuals. The aim of this study was to evaluate if replacing FG with HbA1c to define MetS improves prediction of incident coronary heart disease (CHD) in the Atherosclerosis Risk in Communities (ARIC) cohort. Methods. We included 11,194 ARIC participants without diabetes (based on diagnosis, medication use, FG ≥126 mg/dL, or HbA1c ≥6.5%) or prevalent CHD at baseline (1990-92). Cox proportional hazards models (adjusted for age, race, and study center) were used to compare the association between MetS defined using HbA1c (5.7-6.4%) or FG (100-125 mg/dL, based on ATP III guidelines) and risk of CHD (defined by myocardial infarction or fatal CHD, event data available through 2009). Results. Study participants had a mean age at baseline of 57 years, 43% were male, and 79% were white; median follow-up time was 16 years. Thirty-four percent of the study population had both normal FG (<100 mg/dL) and HbA1c (<5.7%), 37% had elevated FG and normal HbA1c, 4% had normal FG and elevated HbA1c, and 25% had both elevated FG (100-125 mg/dL) and HbA1c (5.7-6.4%). The association of combined FG and HbA1c categories with incident CHD are shown in the Figure. The adjusted hazard ratio predicting for incident CHD from MetS status was 1.43 (95% CI: 1.25-1.63, c-statistic: 0.61) using FG in the definition of MetS and 1.69 (95% CI: 1.48-1.93, c-statistic: 0.62) in the model replacing FG with HbA1c. Conclusions. Incorporating HbA1c into the definition of the MetS may help in identifying individuals who should be targeted for aggressive CHD risk factor reduction. Additionally, HbA1c may be useful clinically and in research settings for identifying individuals with MetS in cases where FG measures are not available.


1998 ◽  
Vol 17 (6) ◽  
pp. 520-529 ◽  
Author(s):  
Peter P. Vitaliano ◽  
James M. Scanlan ◽  
Ilene C. Siegler ◽  
Wayne C. McCormick ◽  
Robert H. Knopp

Sign in / Sign up

Export Citation Format

Share Document